Journal Mobile Options
Table of Contents
Vol. 86, No. 3, 2011
Issue release date: April 2011
Urol Int 2011;86:298–301
(DOI:10.1159/000323655)

Effect of Cordyceps sinensis on Renal Function of Patients with Chronic Allograft Nephropathy

Zhang Z. · Wang X. · Zhang Y. · Ye G.
aDepartment of Urology, Peking University Shougang Hospital, Beijing, and bDepartment of Urology and Renal Transplantation, Center of Nephropathy, Second Affiliated Hospital, Third Military Medical University, Chongqing, China

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Objective: To investigate the effect of Cordyceps sinensis (Bailing Capsule, fermented agent of C. sinensis) on renal function of patients with chronic allograft nephropathy (CAN). Methods: A total of 231 CAN patients who underwent transplantation between 2005 and 2008 and experienced chronic graft dysfunction were randomly divided into 2 groups. Patients in group A (n = 122) were treated with immunosuppressive agents and C. sinensis (2.0 g/day, 3 times a day), while patients in group B (n = 109) were treated with traditional immunosuppressive drugs. Serum creatinine (SCr), blood urea nitrogen (BUN), creatinine clearance rate (CCr) and urinary protein in 24 h (24-hour Upro) of all patients were measured before and after treatment. Urinary concentrations of transforming growth factor (TGF)-β1, retinol-binding protein (RBP) and β2-microglobulin (β2-MG) were detected at the same time. Results: After 6-month treatment with C. sinensis, SCr and CCr in group A were significantly improved (p < 0.05), while there was no significant improvement observed for group B. There was no significant change in BUN in groups A and B (p > 0.05). 24-hour Upro, RBP and β2-MG were lower in group A after treatment with C. sinensis (p < 0.05 or p < 0.01), and urinary TGF-β1 in group A was significantly lower than the values before C. sinensis treatment (p < 0.05), but showed no change in patients of group B. In group A, renal function had improved in 72 cases, stabilized in 38 cases, and worsened in 12 cases. In group B, renal function had improved in 14 cases, stabilized in 50 cases, and worsened in 45 cases (p < 0.05). Conclusion:C. sinensis therapy is advantageous in improving renal function of CAN patients by retarding CAN progression.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Modelli de Andrade LG, Viero RM, Carvalho MFC: Role of peritubular capillaries and vascular endothelial growth factor in chronic allograft nephropathy. Transplant Proc 2009;41:3720–3725.
  2. Huang LF, Liang YZ, Guo FG, Zhou ZF, Cheng BM: Simultaneous separation and determination of active components in Cordyceps sinensis and Cordyceps militarris by LC/ESI-MS. J Pharm Biomed Anal 2003; 33:1155–1162.
  3. Fletcher JT, Nankivell BJ, Alexander SI: Chronic allograft nephropathy. Pediatr Nephrol 2009;24:1465–1471.
  4. Citterio F, Pozzetto U, Romagnoli J, Tondolo E, Silvestri P, Nanni G, Castagneto M: Plasma levels of transforming growth factor-β1 in renal transplant recipients receiving different immunosuppressive regimens. Transplant Proc 2004;36:698–699.
  5. Vazquez MA: Chronic rejection of renal transplants: new clinical insights. Am J Med Sci 2000;320:43–58.
  6. Scherer A, Krause A, Walker JR, Korn A, Niese D, Raulf F: Early prognosis of the development of renal chronic allograft rejection by gene expression profiling of human protocol biopsies. Transplantation 2003;75:1323–1330.
  7. Freese P, Svalander CT, Mölne J, Nordén G, Nyberg G: Chronic allograft nephropathy: biopsy findings and outcome. Nephrol Dial Tansplant 2001;16:2401–2406.
  8. Vadivel N, Tullius SG, Chandraker A: Chronic allograft nephropathy. Semin Nephrol 2007;27:414–429.
  9. Yates PJ, Nicholson ML: The aetiology and pathogenesis of chronic allograft nephropathy. Transpl Immunol 2006;16:148–157.
  10. Sun M, Yang YR, Lu YP, Gao R, Wang L, Wang J, Tang K: Clinical study on application of bailing capsule after renal transplantation (in Chinese). Zhongguo Zhong Xi Yi Jie He Za Zhi 2004;24:808–810.

    External Resources

  11. Chen YP, Deng YY, He XL, et al: Experimental study of Cordyceps in delaying chronic failure. Chin J Integr Tradit West Med Nephrol 2000;1:140–143.
  12. Kahan BD, Karlix JL, Ferguson RM, Leichtman AB, Mulgaonkar S, Gonwa TA, Skerjanec A, Schmouder RL, Chodoff L: Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study. Transplantation 2003;76:1079–1084.
  13. Lu L: Study on effect of Cordyceps sinensis and artemisinin in preventing recurrence of lupus nephritis (in Chinese). Zhongguo Zhong Xi Yi Jie He Za Zhi 2002;22:169–171.

    External Resources

  14. Yang CW, Ahn HJ, Kim WY, Li C, Jung JY, Yoon SA, Kim YS, Cha JH, Kim J, Bang BK: Synergistic effects of mycophenolate mofetil and losartan in a model of chronic cyclosporine nephropathy. Transplantation 2003;75:309–315.
  15. Onozato ML, Tojo A, Kobayashi N, Goto A, Matsuoka H, Fujita T: Dual blockade of aldosterone and angiotensin II additively suppresses TGF-β and NADPH oxidase in the hypertensive kidney. Nephrol Dial Transplant 2007;22:1314–1322.


Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00